



**The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences**  
 Parkinson's Disease Therapeutics Conference  
 New York, NY  
 September 30, 2009

<b>Sept 30, 2009</b>	
8.00	<b>Breakfast</b>
8.30 – 8.45	<b>Welcome by Katie Hood and J. William Langston, MD</b>
8.45 – 10.30	<p><b>Novel Therapeutic Targets</b></p> <p><i>Mathias Baehr, MD, University Hospital Göttingen</i>          “Granulocyte-colony stimulating factor (G-CSF) as a neuroprotective therapy for Parkinson's disease”</p> <p><i>P. Jeffrey Conn, PhD, Vanderbilt University</i>          “Discovery of mGluR4 Potentiators for Symptomatic and Disease-Modifying Treatment of PD”</p> <p><i>David Bumcrot, PhD, Alnylam Pharmaceuticals, Inc.</i>          “Therapeutic Development of siRNA Targeting Alpha-Synuclein”</p>
10.30 – 11.00	<b>Networking Break/Poster Viewing</b>
11:00 – 12.00	<p><b>Novel Therapeutic Targets (cont'd)</b></p> <p><i>David Standaert, MD, PhD, University of Alabama at Birmingham</i>          “Validation of VPS41, A Protein involved in Lysosomal Trafficking, as a Target for Parkinson Disease Therapy”</p> <p><i>Gretchen L. Snyder, PhD, Intra-Cellular Therapies, Inc.</i>          “Novel Phosphodiesterase Inhibitors for Parkinson's Disease”</p>
12.00 – 1.15	<b>Lunch/Poster Viewing</b>
1.15 – 3.15	<p><b>Research Tools and Resources</b></p> <p><i>Krystof Bankiewicz, MD, PhD, University of California, San Francisco</i>          “Image-Guided Convective Delivery of AAV Vectors”</p> <p><i>Susan Bressman, MD, Beth Israel Medical Center</i>          “Parkinson's Disease, Ashkenazi Jews and LRRK2”</p> <p><i>Robert L. Nussbaum, MD, University of California, San Francisco</i>          “P1 Artificial Chromosome Transgenic Mice as models for Progressive Parkinson Disease”</p> <p><i>Michael G. Schlossmacher, MD, University of Ottawa</i>          “Characterization of Alpha Synuclein in Human Fluids &amp; Brain as a Biomarker for PD”</p>

3.15 – 3.45	<b>Networking Break/Poster Viewing</b>
3.45 – 4.45	<b>Hot Topics in PD</b>  <i>Franz Hefti, PhD, Avid Radiopharmaceuticals, Inc.</i> “How Should One Design the First Alpha-Synuclein Efficacy Trial?”  <i>Andrew Singleton, PhD, National Institute on Aging/NIH</i> “(How) Can GWAS Help Drug Developers?”
4.45 – 5.00	<b>Closing Remarks</b>
5.00 – 7.00	<b>Cocktail Reception/Poster Viewing</b>